A Phase 2 interventional study of rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 15 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-01.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 74th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2005, is one of 94 in phase 2, and was the 116th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 11 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2005, is one of 8 in phase 2, and was the 17th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab
1
Also known as: MabThera/Rituxan
Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date
Percentage of participants who at 2 years from the start of treatment remained free from documented disease progression, relapse, or death. Failure status was based on tumor evaluation performed on Month 28. Participants who did not have a tumor evaluation at Month 28 were counted as failures.
Time frame: Month 28
Percentage of Participants Achieving a Best Overall Response of CR, CRu, or PR by Study Phase
CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.
Time frame: Baseline, Months 4, 7 (Induction Phase), 11, 16 (Maintenance Phase),22, 28, 34, and 40(Follow-Up Phase)
Percentage of Participants Achieving a Response by Response Type and Study Phase
CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.
Time frame: Baseline, Months 4, 7, 11, 16, 22, 28, 34, and 40
Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death
FFS data were analyzed using Kaplan-Meier survival analysis. FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or dropped out due to adverse events (AE) were censored at their last assessment date. The reported data refer to values up to 40 months.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
FFS - Percentage of Participants With an Event
FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or who dropped out due to AEs were censored at their last assessment date.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
FFS - Time to Event
FFS was measured from the date of treatment start to the date of documented disease progression, relapse or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent or dropped out due to AEs were censored at their last assessment date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Overall Survival (OS) - Percentage of Participants Estimated to be Alive
OS data were analyzed using Kaplan-Meier survival analysis. OS was defined as the time from first dosage of study drug to the date of death from any cause. Reported data refer to values up to 40 months.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
OS - Percentage of Participants With an Event
OS was defined as the time from first dosage of study drug to the date of death from any cause.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
OS - Time to Event
Overall survival was defined as the time from first dosage of study drug to the date of death from any cause.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free
DFS data were analyzed using Kaplan-Meier survival analysis. DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of CR to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored as of the death date. The reported data refer to values up to 40 months.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
DFS - Percentage of Participants With an Event
DFS was defined for all patients who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
DFS - Time to Event
DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free
PFS data were analyzed using Kaplan-Meier survival analysis. PFS was defined as the time from treatment start to the date of documented disease progression. Reported data refer to values up to 40 months.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
PFS - Percentage of Participants With an Event
Progression-free survival was defined as the time from the date of treatment start to the date of documented disease progression.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
PFS - Time to Event
Progression-free survival was defined as the time from treatment start to the date of documented disease progression. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response
DR data were analyzed using Kaplan-Meier survival analysis. DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
DR - Percentage of Participants With an Event
DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
DR - Time to Event
DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 47 |
| Completed | 44 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 44 |
| Completed | 41 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Clinical relapse | 1 |
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 41 |
| Completed | 37 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Disease progression | 2 |
Percentage of participants who at 2 years from the start of treatment remained free from documented disease progression, relapse, or death. Failure status was based on tumor evaluation performed on Month 28. Participants who did not have a tumor evaluation at Month 28 were counted as failures.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date | 73.9 (61.22 to 86.60) |
CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Induction Phase | 95.7 (89.76 to 100.00) |
| Maintenance Phase | 80.4 (68.97 to 91.90) |
CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| CR at end of induction phase | 41.3 |
| CR at end of maintenance phase | 45.7 |
| CR at final assessment | 45.7 |
| CRu at end of induction phase | 21.7 |
| CRu at end of maintenance phase | 15.2 |
| CRu at final assessment | 19.6 |
| PR at end of induction phase | 32.6 |
| PR at end of maintenance phase | 19.6 |
| PR at final assessment | 13.0 |
| Relapse at end of induction phase | 0 |
| Relapse at end of maintenance phase | 0 |
| Relapse at final assessment | 2.2 |
| Unknown at end of induction phase | 4.3 |
| Unknown at end of maintenance phase | 19.6 |
| Unknown at final assessment | 19.6 |
FFS data were analyzed using Kaplan-Meier survival analysis. FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or dropped out due to adverse events (AE) were censored at their last assessment date. The reported data refer to values up to 40 months.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death | 90.12 (75.48 to 96.23) |
FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or who dropped out due to AEs were censored at their last assessment date.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| FFS - Percentage of Participants With an Event | 8.7 |
FFS was measured from the date of treatment start to the date of documented disease progression, relapse or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent or dropped out due to AEs were censored at their last assessment date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| FFS - Time to Event | 39.14 ± 0.70 |
OS data were analyzed using Kaplan-Meier survival analysis. OS was defined as the time from first dosage of study drug to the date of death from any cause. Reported data refer to values up to 40 months.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Overall Survival (OS) - Percentage of Participants Estimated to be Alive | 97.44 (83.16 to 99.64) |
OS was defined as the time from first dosage of study drug to the date of death from any cause.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| OS - Percentage of Participants With an Event | 2.17 |
Overall survival was defined as the time from first dosage of study drug to the date of death from any cause.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| OS - Time to Event | 38.6 ± NA |
DFS data were analyzed using Kaplan-Meier survival analysis. DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of CR to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored as of the death date. The reported data refer to values up to 40 months.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free | 87.70 (65.84 to 95.96) |
DFS was defined for all patients who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| DFS - Percentage of Participants With an Event | 10.34 |
DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| DFS - Time to Event | 32.51 ± 0.58 |
PFS data were analyzed using Kaplan-Meier survival analysis. PFS was defined as the time from treatment start to the date of documented disease progression. Reported data refer to values up to 40 months.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free | 90.12 (75.48 to 96.23) |
Progression-free survival was defined as the time from the date of treatment start to the date of documented disease progression.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| PFS - Percentage of Participants With an Event | 8.70 |
Progression-free survival was defined as the time from treatment start to the date of documented disease progression. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| PFS - Time to Event | 39.14 ± 0.70 |
DR data were analyzed using Kaplan-Meier survival analysis. DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response | 90.07 (75.45 to 96.19) |
DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| DR - Percentage of Participants With an Event | 9.09 |
DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| DR - Time to Event | 32.19 ± 0.72 |
Collected over Treatment-emergent adverse events (AEs) were reported throughout the study (up to 40 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Fludarabine + Cyclophosphamide | — | 16/47 (34%) | 47/47 (100%) |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| PneumoniaInfections and infestations | 3/47 |
| NeutropeniaBlood and lymphatic system disorders | 2/47 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/47 |
| Mitral valve incompetenceCardiac disorders | 1/47 |
| Renal dysplasiaCongenital, familial and genetic disorders | 1/47 |
| PyrexiaGeneral disorders | 1/47 |
| CholecystitisHepatobiliary disorders | 1/47 |
| BronchopneumoniaInfections and infestations | 1/47 |
| Staphylococcal infectionInfections and infestations | 1/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/47 |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 29/47 |
| PyrexiaGeneral disorders | 23/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/47 |
| NauseaGastrointestinal disorders | 20/47 |
| LeukopeniaBlood and lymphatic system disorders | 18/47 |
| AstheniaGeneral disorders | 16/47 |
| StomatitisGastrointestinal disorders | 10/47 |
| AnaemiaBlood and lymphatic system disorders | 8/47 |
| Herpes zosterInfections and infestations | 8/47 |
| BronchitisInfections and infestations | 6/47 |
Intent-to-Treat (ITT) population: all enrolled participants who completed at least 2 cycles of treatment.
| Age, Continuous(years) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Mean | 57.3 ± 8.2 |
| Sex: Female, Male(Participants) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Female | 18 |
| Male | 28 |
Ran from Jul 2005 to primary completion in Sep 2010, 62 months.
Results were first posted in Aug 2014, 3 years 10 months after primary completion.
Of 50 industry-sponsored phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 62 months is above that.
Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab